How Bridging Studies Support Global Marketing Authorization Applications

Introduction: Why Bridging Studies Matter in Global Drug Approvals

In today’s global pharmaceutical landscape, companies increasingly aim for simultaneous or sequential marketing authorizations across multiple regions—such as the U.S., Europe, and Asia. However, regulatory agencies often require region-specific data to account for potential differences in drug response due to ethnic, environmental, or clinical practice factors. This is where bridging studies play a critical role.

Bridging studies are designed to provide additional data that “bridge” foreign clinical trial results to the local population. By assessing pharmacokinetics (PK), pharmacodynamics (PD), and safety in a specific ethnic group, these studies support the extrapolation of foreign data and minimize the need for duplicative full-scale trials.

This article discusses the design, purpose, regulatory expectations, and strategic role of bridging studies in the context of global Marketing Authorization Applications (MAAs), with specific focus on EMA, FDA, and Japan’s PMDA.

ICH E5 Guideline: The Foundation for Bridging Studies

The ICH E5 guideline, “Ethnic Factors in the Acceptability of Foreign Clinical Data,” is the international standard that defines when and how bridging studies may be required. It addresses:

• Intrinsic ethnic factors (e.g., genetics, metabolism, diet, age)
• Extrinsic factors (e.g., healthcare infrastructure, clinical practice)
• Criteria for acceptability of foreign data
• Design and analysis of bridging studies

Bridging studies are especially relevant in submissions to regulatory authorities like Japan’s PMDA and in EMA procedures involving extrapolation from non-European populations. In contrast, the FDA often accepts global clinical data if trial diversity and data integrity are strong, though bridging may still be required for certain populations.

Types of Bridging Studies: PK, PD, and Clinical Confirmation

Bridging studies vary based on the information gap identified by regulators. Common types include:

• Pharmacokinetic (PK) Bridging: Compares drug absorption, distribution, metabolism, and elimination between populations.
• Pharmacodynamic (PD) or Biomarker-Based Bridging: Compares mechanism-of-action or biological markers.
• Clinical Bridging Studies: Shorter efficacy/safety studies in the local population to validate extrapolation.

Example: A U.S.-based clinical trial for a monoclonal antibody may be supported by a Japanese PK bridging study comparing exposure levels in 30 healthy Japanese volunteers to 30 non-Asian subjects, demonstrating comparable AUC and Cmax values.

Regulatory Expectations, Case Studies, and Best Practices in Bridging Strategy

EMA Expectations for Bridging Studies

The EMA generally accepts global clinical data submitted in MAAs, provided the study population includes adequate European representation. Bridging studies are usually not required if:

• The drug shows consistent PK/PD across regions
• Ethnic sensitivity is minimal (e.g., in monoclonal antibodies)
• Multiregional Clinical Trials (MRCTs) already include EU participants

However, if pivotal studies are conducted entirely outside the EU—particularly in Asia or Latin America—EMA may request:

• Additional PK studies in European patients
• Real-world evidence from EU practice settings
• Bridging justifications in Module 2.5 (Clinical Overview)

Bridging Study Design: Sample Sizes and Statistical Considerations

Most PK bridging studies use small sample sizes (n=20–50 per arm), randomized 1:1 to compare ethnic groups. Key design elements include:

• Primary endpoints: AUC, Cmax, Tmax
• Statistical analysis: Geometric mean ratio (GMR), 90% confidence intervals (CI)
• Acceptance range: GMR within 80–125% (bioequivalence criteria)

Example dummy table:

Japan: A Region with Stringent Bridging Requirements

Japan’s PMDA often mandates region-specific data. Bridging strategies are essential for MAAs filed in Japan, especially when the development program originates in the U.S. or EU. Strategies include:

• Dedicated Japanese PK studies
• Use of local Phase 1 and Phase 3 bridging arms
• Pre-submission consultations with PMDA

Sponsors frequently conduct parallel development, integrating Japanese subjects early in the program to avoid standalone bridging studies.

Bridging Data in Biosimilar and Vaccine Submissions

Bridging is critical in biosimilar submissions where minor PK differences may lead to significant changes in efficacy or immunogenicity across populations. Similarly, vaccine MAAs require region-specific immune response and safety data due to potential differences in baseline immunity and pathogen exposure.

For example, a dengue vaccine developed in Latin America may require bridging data from Southeast Asian populations to support submission in Thailand or Indonesia.

Regulatory Submission Strategy and Justification

The bridging strategy should be:

• Explained in Module 2.5 and 2.7 (Clinical Overview and Summaries)
• Supported by ethnic sensitivity analysis in Module 5.3
• Aligned with prior scientific advice or protocol assistance
• Included in the overall risk–benefit evaluation

Sponsors should also include bridging study protocols and reports in Module 5.3.1 (Clinical Study Reports – Pharmacokinetics).

Case Study: Bridging Study in Global Oncology Submission

A global oncology sponsor filed an MAA based on a U.S.-based Phase 3 study. EMA requested additional exposure and safety data in Europeans due to:

• Lack of EU enrollment in pivotal trial
• Suspected PK variability in CYP2D6 metabolizers

The sponsor rapidly conducted a Phase 1 bridging study in 36 EU cancer patients, demonstrating consistent exposure. EMA accepted the data, and the MAA was approved 14 months post-submission.

Conclusion: Bridging Science and Regulation

Bridging studies are not mere technicalities—they are critical enablers of global regulatory alignment and public health. By scientifically addressing ethnic differences, sponsors can streamline global development and reduce the need for full-scale duplication across regions.

Whether filing with the EMA, PMDA, or other national agencies, an effective bridging strategy should be rooted in ICH E5 guidance, tailored to the drug’s characteristics, and justified clearly in the MAA. With proper planning, sponsors can reduce timelines, lower development costs, and bring innovation to patients worldwide.

Mastering Multiregional Clinical Trials with ICH E5 and E17 Guidelines

Conducting clinical trials across multiple regions has become increasingly essential for pharmaceutical companies aiming for simultaneous global drug approvals. To address the complexity of such trials, the International Council for Harmonisation (ICH) introduced guidelines specifically for multiregional clinical trials (MRCTs), namely ICH E5 and ICH E17. These guidelines promote standardization and ensure that data from diverse populations can be used effectively to support regulatory submissions worldwide.

In this article, we will delve into the objectives, principles, and implementation of ICH E5 and E17, offering insights into how sponsors can design and execute MRCTs in compliance with regulatory expectations from agencies like EMA, CDSCO, and USFDA.

Overview of ICH E5: Ethnic Factors in Clinical Data Bridging

ICH E5, titled “Ethnic Factors in the Acceptability of Foreign Clinical Data,” was one of the earlier efforts to recognize how demographic and cultural differences might impact the safety, efficacy, or dosage of a drug across populations. The guideline provides a framework to determine if clinical data from one region can be extrapolated to another through a concept called a bridging study.

Key Elements of ICH E5:

• Identification of intrinsic (genetic, age, gender) and extrinsic (diet, environment, medical practice) ethnic factors
• Assessment of the impact of ethnic differences on drug response
• Designing bridging studies to demonstrate comparability in regional populations
• Facilitating the use of foreign clinical data with limited regional data

For example, a clinical trial conducted in Europe may require supplemental bridging data before it is accepted in Japan. ICH E5 allows for a systematic way to address these needs.

ICH E17: The Unified Approach for MRCTs

Recognizing the growing trend toward globally synchronized submissions, ICH released E17, “General Principles for Planning and Design of MRCTs.” Unlike E5, which focuses on regional bridging, E17 provides a holistic framework for the design and conduct of multiregional studies from the outset.

Key Components of ICH E17:

1. Global Development Strategy: Encourages harmonized trial design from the early phases to avoid duplication.
2. Single Protocol: Use of a unified core protocol that accommodates regional requirements while maintaining data integrity.
3. Sample Size Allocation: Ensures statistically valid representation from each region for regulatory acceptability.
4. Ethnic Factor Consideration: Incorporates ICH E5 principles in planning trial diversity.
5. Data Pooling and Analysis: Promotes combined data analysis while allowing for region-specific assessments when needed.

MRCTs conducted under E17 principles reduce regulatory lag, optimize resources, and ensure that global patient populations are represented.

Designing a MRCT: Step-by-Step Process

To effectively implement ICH E17 and E5, sponsors must plan trials with precision:

1. Establish Core Protocol:

• Define the study objectives and endpoints relevant across regions
• Use globally harmonized ICF templates and standard-of-care practices

2. Address Regional Sensitivities:

• Evaluate local medical practices, dosing, and patient behavior
• Adapt operational strategies without altering scientific validity

3. Plan Sample Size Allocation:

• Ensure each region contributes enough subjects to allow subgroup analyses
• Consider statistical power in light of geographic variability

4. Implement Real-Time Monitoring:

• Use centralized systems to monitor site performance globally
• Ensure protocol adherence and data consistency across all regions

For effective documentation and execution, organizations should utilize Pharma SOPs tailored to global trial conduct.

Bridging vs MRCT: When to Choose What?

The choice between using existing foreign data (ICH E5) and conducting a full MRCT (ICH E17) depends on the development stage and target markets:

Challenges in MRCT Implementation

• Regulatory divergence in protocol and data requirements
• Patient recruitment and retention across cultural contexts
• Logistics and supply chain complexity
• Need for multilingual documentation and training

These challenges underscore the importance of using robust Stability Studies data and region-appropriate training plans.

Benefits of ICH-Guided MRCTs

• Global data acceptability with reduced duplication
• Faster time to market through simultaneous submissions
• Improved data quality and consistency
• Cost savings through harmonized operations

Global Regulatory Acceptance

Regulators such as the South African Health Products Regulatory Authority and Health Canada encourage MRCTs aligned with ICH E17 for new drug applications. However, regional feedback during protocol submission remains essential.

Best Practices for MRCT Success

1. Engage early with regulatory agencies to discuss protocol design
2. Use common data standards (e.g., CDISC, MedDRA)
3. Incorporate real-world data for supportive evidence
4. Implement multilingual site training and centralized monitoring
5. Adopt adaptive trial designs when possible

Conclusion

ICH guidelines E5 and E17 offer a strategic blueprint for designing and conducting multiregional clinical trials. While E5 facilitates regional data bridging, E17 enables full-scale MRCTs that satisfy global regulatory expectations. By harmonizing protocol design, understanding ethnic sensitivities, and planning operations regionally, sponsors can increase the likelihood of faster, broader drug approvals across international markets.